Pakistan Drug Prices Up 4%

3 March 1997

The Pakistan caretaker government of Meraj Kahid has allowed a 4%increase in drug prices, Health Secretary Zaheer Sajjad has confirmed, because of the 10% sales tax on raw material imports imposed recently.

The rises will be for both controlled and decontrolled drugs, but prices of drugs imported as finished products will not be affected. Most of the increases will involve drugs manufactured locally using raw materials imported from abroad, ie the bulk of the Pakistani drug market.

A 5% sales tax on imported drug raw materials was applied in October by the Bhutto regime, and a further 5% was added by the caretaker government. Following this, a number of multinational drugmakers approached the Ministry of Health, which then proposed to the government that either the sales tax on raw material imports be withdrawn or companies be allowed to increase prices.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight